Lung

Lung
2025-05-16T00:00:00.000+10:00
Ongoing

CA224-1093

CA224-1093
Non-small cell lung cancer (NSCLC)

A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%

A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%.

Trial overview

Clinical Area

Medical Oncology

Disease

Non-small cell lung cancer (NSCLC)

Disease site

Lung & bronchus

Study Phase

III

Trial Identifiers

Registration number: NCT06561386

https://clinicaltrials.gov/study/NCT06561386

GenesisCare Location(s)
Principal Investigator(s)
Medical Oncologist

Prof. Nick Pavlakis

BSc MBBS MMed PhD FRACP

Prof. Nick Pavlakis
location pin icon

Frenchs Forest (Oncology) +1

View Profile
Profile Image - Prof. Nick Pavlakis

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.